Recursion Pharmaceuticals (NASDAQ:RXRX) Director Sells $12,602.34 in Stock

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Director Namandje Bumpus sold 3,963 shares of the stock in a transaction on Thursday, June 18th. The shares were sold at an average price of $3.18, for a total value of $12,602.34. Following the completion of the transaction, the director directly owned 127,632 shares in the company, valued at approximately $405,869.76. This represents a 3.01% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Namandje Bumpus also recently made the following trade(s):

• On Wednesday, June 3rd, Namandje Bumpus sold 4,386 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $3.54, for a total value of $15,526.44.

Recursion Pharmaceuticals Trading Up 2.2%

Shares of RXRX stock opened at $3.23 on Thursday. The business has a 50-day moving average price of $3.31 and a two-hundred day moving average price of $3.71. Recursion Pharmaceuticals, Inc. has a 12-month low of $2.77 and a 12-month high of $7.18. The company has a quick ratio of 5.47, a current ratio of 5.47 and a debt-to-equity ratio of 0.01. The firm has a market cap of $1.71 billion, a P/E ratio of -2.69 and a beta of 1.04.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its quarterly earnings data on Wednesday, May 6th. The company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.30) by $0.08. The firm had revenue of $6.47 million for the quarter, compared to analyst estimates of $15.78 million. Recursion Pharmaceuticals had a negative return on equity of 54.33% and a negative net margin of 842.95%.The company’s revenue was down 56.8% on a year-over-year basis. During the same period in the prior year, the company earned ($0.50) EPS. Equities analysts anticipate that Recursion Pharmaceuticals, Inc. will post -0.99 EPS for the current fiscal year.

Hedge Funds Weigh In On Recursion Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of RXRX. International Assets Investment Management LLC bought a new stake in Recursion Pharmaceuticals in the fourth quarter valued at approximately $31,000. Integral Investment Advisors Inc. purchased a new stake in shares of Recursion Pharmaceuticals during the first quarter valued at approximately $39,000. Sequoia Financial Advisors LLC bought a new position in shares of Recursion Pharmaceuticals in the fourth quarter worth approximately $41,000. MQS Management LLC bought a new position in shares of Recursion Pharmaceuticals in the first quarter worth approximately $41,000. Finally, Allworth Financial LP increased its stake in shares of Recursion Pharmaceuticals by 85.6% in the third quarter. Allworth Financial LP now owns 9,548 shares of the company’s stock worth $47,000 after buying an additional 4,403 shares during the period. 89.06% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several research firms have commented on RXRX. JPMorgan Chase & Co. decreased their price target on shares of Recursion Pharmaceuticals from $11.00 to $10.00 and set an “overweight” rating on the stock in a research note on Thursday, April 30th. Bank of America lowered their price objective on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a “neutral” rating for the company in a report on Wednesday, February 25th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a report on Tuesday, April 21st. Morgan Stanley lifted their target price on shares of Recursion Pharmaceuticals from $5.00 to $5.50 and gave the stock an “equal weight” rating in a research report on Thursday, May 14th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $8.00 target price on shares of Recursion Pharmaceuticals in a research report on Thursday, May 7th. Two equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $8.10.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.